Recent therapeutic advances have changed the treatment landscape of metastatic renal cell carcinoma. Unfortunately, the seven agents now available are not based on biomarkers that would indicate ...

Our study demonstrates that MGd alone is not sufficient to generate a response in patients with metastatic RCC. It does demonstrate, however, that even repeated doses of MGd are reasonably ...

Data were censored on the last follow-up if the patient was alive. Separate analyses were performed according to International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group.